According to the Complaint, Edge Therapeutics, Inc. ("Edge") operates as a clinical-stage biotechnology company to discover, develop and commercialize hospital-based therapies for the management of acute, life-threatening neurological conditions.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company’s lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and, (2) that as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Edge’s business, operations, and prospects were materially false and misleading at all relevant times.

On December 7, 2018, the Court issued an Order appointing Lead Plaintiffs and Counsel. On February 19, 2019, Lead Plaintiffs voluntarily dismissed this case.